热门标签

手机新2管理端:Sanofi ends cancer drug trials

时间:4周前   阅读:13

在线博彩平台www.hg108.vip)是皇冠体育官网线上直营平台。在线博彩平台面向亚太地区招募代理,开放皇冠信用网代理申请、皇冠现金网代理会员开户等业务。在线博彩平台可下载皇冠官方APP,皇冠APP包括皇冠体育最新代理登录线路、皇冠体育最新会员登录线路。

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.

The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.

,

手机新2管理端www.99cx.vip)实时更新发布最新最快最有效的手机新2管理端网址,包括新2手机网址,新2备用网址,皇冠最新网址,新2足球网址,新2网址大全。

,

Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.

Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.

UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg


转载说明:本文转载自Sunbet。

上一篇:足球博彩app:Smaller net loss for Pos Malaysia in 2Q

下一篇:皇冠网址(www.hg108.vip):Ringgit ends lower against US dollar

网友评论